American Society of Health-System Pharmacists, Bethesda, MD, USA.
Am J Health Syst Pharm. 2013 Aug 15;70(16):1414-27. doi: 10.2146/ajhp130112.
The evolution of sterile compounding in the context of hospital patient care, the evolution of related technology, past incidents of morbidity and mortality associated with preparations compounded in various settings, and efforts over the years to improve compounding practices are reviewed.
Tightened United States Pharmacopeial Convention standards (since 2004) for sterile compounding made it difficult for hospitals to achieve all of the sterile compounding necessary for patient care. Shortages of manufactured injections added to the need for compounding. Non-hospital-based compounding pharmacies increased sterile compounding to meet the needs. Gaps in federal and state laws and regulations about compounding pharmacies led to deficiencies in their regulation. Lapses in sterility led to injuries and deaths. Perspectives offered include potential actions, including changes in practitioner education, better surveillance of sterile compounding, regulatory reforms, reexamination of the causes of drug shortages, and the development of new technologies.
Over the years, there have been numerous exhortations for voluntary better performance in sterile compounding. In addition, professional leadership has been vigorous and extensive in the form of guidance, publications, education, enforceable standards, and development of various associations and organizations dealing with safe compounding practices. Yet problems continue to occur. We must engage in diligent learning from the injuries and tragedies that have occurred. Assuming that we are already doing all we can to avoid problems would be an abdication of the professional mission of pharmacists. It would be wrong thinking to assume that the recent problems in large-scale compounding pharmacies are the only problems that warrant attention. It is time for a systematic assessment of the nature and the dimensions of the problems in every type of setting where sterile compounding occurs. It also is time for some innovative thinking about ensuring safety in sterile compounding.
回顾医院患者护理中无菌调配的演变、相关技术的演变、与在各种环境下配制相关的发病率和死亡率事件,以及多年来为改进调配实践所做的努力。
自 2004 年以来,美国药典(USP)对无菌调配的严格标准使得医院难以完成所有必要的无菌调配以满足患者护理需求。已上市注射剂的短缺加剧了无菌调配的需求。非医院背景的调配药房增加了无菌调配以满足需求。联邦和州关于调配药房的法律法规存在空白,导致对其监管存在缺陷。无菌性的疏忽导致了伤害和死亡。提供的观点包括潜在的行动,包括改变从业者教育、更好地监测无菌调配、监管改革、重新审视药物短缺的原因以及开发新技术。
多年来,一直有人呼吁在无菌调配方面自愿提高绩效。此外,专业领导层通过指导、出版物、教育、可执行标准以及各种与安全调配实践相关的协会和组织的发展,以积极广泛的方式提供领导。然而,问题仍然存在。我们必须从已经发生的伤害和悲剧中勤奋学习。假设我们已经在尽一切努力避免问题,那将是对药剂师专业使命的放弃。假设最近大型调配药房的问题是唯一需要关注的问题,那将是错误的想法。现在是对每个发生无菌调配的环境中问题的性质和范围进行系统评估的时候了。现在也是时候对确保无菌调配安全进行一些创新性思考了。